Incidence of definite stent thrombosis or in-stent restenosis after drug-eluting stent implantation for treatment of coronary in-stent restenosis: From Western Denmark heart registry

Catheterization and Cardiovascular Interventions

Volumn 81, Issue 2, 2013, Pages 260-265

  Jensen, Jesper Khedri ^a   Jensen, Lisette Okkels ^a   Terkelsen, Christian Juhl ^b   Lassen, Jens Flensted ^b   Tilsted, Hans Henrik ^b   Hansen, Knud Noerregaard ^a   Maeng, Michael ^b   Thuesen, Leif ^b   Thayssen, Per ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

angiography; coronary; percutaneous coronary intervention; restenosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PACLITAXEL; RAPAMYCIN; ZOTAROLIMUS;

ADULT; AGING; ARTERY LESION; ARTICLE; BARE METAL STENT; CLINICAL FEATURE; COHORT ANALYSIS; CORONARY ARTERY OBSTRUCTION; CORONARY ARTERY THROMBOSIS; CORONARY STENT; DENMARK; DISEASE DURATION; DISEASE REGISTRY; DRUG ELUTING STENT; FEMALE; HEART MUSCLE REVASCULARIZATION; HOSPITAL ADMISSION; HUMAN; IMPLANTATION; IN-STENT RESTENOSIS; INCIDENCE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; POPULATION RESEARCH; PROGNOSIS; REOPERATION; STABLE ANGINA PECTORIS; STENT THROMBOSIS; TARGET LESION REVASCULARIZATION; TREATMENT INDICATION; UNSTABLE ANGINA PECTORIS;

AGED; ANGINA PECTORIS; CORONARY RESTENOSIS; DENMARK; DRUG-ELUTING STENTS; FEMALE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; METALS; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PROSTHESIS DESIGN; RECURRENCE; REGISTRIES; RISK FACTORS; THROMBOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84874505203     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.24398     Document Type: Article

References (27)

1. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-1780.
2. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-1323.
3. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221-231.
4. Chen MS, John JM, Chew DP, Lee DS, Ellis SG, Bhatt DL,. Bare metal stent restenosis is not a benign clinical entity. Am Heart J 2006; 151: 1260-1264.
5. Abdel-Wahab M, Nienaber CA, Mostafa AE, et al. Clinical outcome of percutaneous treatment of in-stent restenosis with drug-eluting stents: Results from the first phase of the prospective multicentre German DES.DE registry. EuroIntervention 2011; 7: 201-208.
6. Kastrati A, Dibra A, Eberle S, Mehilli J, Suarez de Lezo J, Goy JJ, Ulm K, Schomig A,. Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: Meta-analysis of randomized trials. JAMA 2005; 294: 819-825.
7. Mishkel GJ, Moore AL, Markwell S, Shelton MC, Shelton ME,. Long-term outcomes after management of restenosis or thrombosis of drug-eluting stents. J Am Coll Cardiol 2007; 49: 181-184.
8. Mehilli J, Byrne RA, Tiroch K, Pinieck S, Schulz S, Kufner S, Massberg S, Laugwitz KL, Schomig A, Kastrati A,. Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: The ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study. J Am Coll Cardiol 2010; 55: 2710-2716.
9. Abe M, Kimura T, Morimoto T, et al. Sirolimus-eluting stent versus balloon angioplasty for sirolimus-eluting stent restenosis: Insights from the j-Cypher Registry. Circulation 2010; 122: 42-51.
10. Latib A, Mussardo M, Ielasi A, et al. Long-term outcomes after the percutaneous treatment of drug-eluting stent restenosis. JACC Cardiovasc interv 2011; 4: 155-164.
11. Jensen LO, Maeng M, Kaltoft A, et al. Stent thrombosis, myocardial infarction, and death after drug-eluting and bare-metal stent coronary interventions. J Am Coll Cardiol 2007; 50: 463-470.
12. Jensen LO, Tilsted HH, Thayssen P, et al. Paclitaxel and sirolimus eluting stents versus bare metal stents: long-term risk of stent thrombosis and other outcomes. From the Western Denmark Heart Registry. EuroIntervention 2010; 5: 898-905.
13. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007; 115: 2344-2351.
14. Steinberg DH, Gaglia MA Jr, Pinto Slottow TL, et al. Outcome differences with the use of drug-eluting stents for the treatment of in-stent restenosis of bare-metal stents versus drug-eluting stents. Am J Cardiol 2009; 103: 491-495.
15. Worthley MI, Anderson TJ, Traboulsi M, Charbonneau F, Curtis MJ, Hansen JL, Knudtson ML, Spence FP, Goodhart DM,. Registry data evaluating the effectiveness of drug-eluting stents for the treatment of symptomatic in-stent restenosis. Heart Lung Circ 2006; 15: 300-305.
16. Anderson RA, Fath-Ordoubadi F, Younas S, Bainbridge A, Swallow RA, Dawkins KD, Curzen NP,. Drug-eluting stents for the treatment of in-stent restenosis-'real world' double centre experience in consecutive patients. Int J Cardiovasc Interv 2005; 7: 188-192.
17. Cosgrave J, Melzi G, Corbett S, et al. Repeated drug-eluting stent implantation for drug-eluting stent restenosis: The same or a different stent. Am Heart J 2007; 153: 354-359.
18. Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, Mehran R,. In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol 2010; 56: 1897-1907.
19. Kim YH, Lee BK, Park DW, Park KH, Choi BR, Lee CW, Hong MK, Kim JJ, Park SW, Park SJ,. Comparison with conventional therapies of repeated sirolimus-eluting stent implantation for the treatment of drug-eluting coronary stent restenosis. Am J Cardiol 2006; 98: 1451-1454.
20. Kornowski R, Hong MK, Tio FO, Bramwell O, Wu H, Leon MB,. In-stent restenosis: Contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol 1998; 31: 224-230.
21. Nebeker JR, Virmani R, Bennett CL, et al. Hypersensitivity cases associated with drug-eluting coronary stents: A review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol 2006; 47: 175-181.
22. Kastrati A, Dibra A, Mehilli J, Mayer S, Pinieck S, Pache J, Dirschinger J, Schomig A,. Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents. Circulation 2006; 113: 2293-2300.
23. Zahn R, Hamm CW, Schneider S, et al. Incidence and predictors of target vessel revascularization and clinical event rates of the sirolimus-eluting coronary stent (results from the prospective multicenter German Cypher Stent Registry). Am J Cardiol 2005; 95: 1302-1308.
24. Zahn R, Hamm CW, Schneider S, Richardt G, Kelm M, Levenson B, Bonzel T, Tebbe U, Sabin G, Nienaber CA,. Coronary stenting with the sirolimus-eluting stent in clinical practice: Final results from the prospective multicenter German Cypher Stent Registry. J Interv Cardiol 2010; 23: 18-25.
25. Appleby CE, Khattar RS, Morgan K, Clarke B, Curzen N, Neyses L, Fath-Ordoubadi F,. Drug eluting stents for the treatment of bare metal in-stent restenosis: long-term outcomes in real world practice. EuroIntervention 2011; 6: 748-753.
26. Almalla M, Schroder JW, Pross V, Stegemann E, Marx N, Hoffmann R,. Everolimus-eluting versus Paclitaxel-eluting stents for treatment of bare metal stent restenosis. Am J Cardiol 2011; 108: 518-522.
27. Kastrati A, Mehilli J, von Beckerath N, Dibra A, Hausleiter J, Pache J, Schuhlen H, Schmitt C, Dirschinger J, Schomig A,. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA 2005; 293: 165-171.